Literature DB >> 23123184

Changes in Interleukin-1 alpha serum levels after transplantation of umbilical cord blood cells in a model of perinatal hypoxic-ischemic brain damage.

Katja Rosenkranz1, Matthias Tenbusch, Caroline May, Katrin Marcus, Carola Meier.   

Abstract

Transplantation of human umbilical cord blood (hUCB) cells is a potential approach for the treatment of perinatal hypoxic-ischemic brain injury. Neurological and motor deficits resulting from the brain lesion are ameliorated upon transplantation. The molecular mechanisms underlying these improvements are currently being unravelled. One parameter identified as part of the beneficial effects of hUCB cells is the reduction of brain inflammation. It is, however, unclear whether the modulation of brain inflammation is due to local or systemic effects of hUCB cells. In this study, the effects of hUCB cell transplantation in a model of perinatal hypoxic-ischemic brain injury were investigated at the systemic level by measurement of serum levels of pro-inflammatory cytokines by multiplex bead arrays. Two days after induction of the brain damage, levels of the pro-inflammatory cytokines Interleukin-1α (IL-1α), Interleukin-1β (IL-1β), and Tumor necrosis factor α (TNFα) were increased in the serum of rats. Application of hUCB cells, in turn, correlated with a reduced elevation of serum levels of these pro-inflammatory cytokines. This decrease was accompanied by a reduced expression of CD68, a marker protein of activated microglia/macrophages in the brain. Therefore, systemic modulation of the immune response by hUCB cells could represent one possible mechanism of how these cells might mediate their beneficial effects. Creation of a regenerative environment with reduced inflammation might account for the functional regeneration observed upon hUCB cell treatment in lesioned animals. Published by Elsevier GmbH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23123184     DOI: 10.1016/j.aanat.2012.09.003

Source DB:  PubMed          Journal:  Ann Anat        ISSN: 0940-9602            Impact factor:   2.698


  6 in total

Review 1.  Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy.

Authors:  Makoto Nabetani; Haruo Shintaku; Takashi Hamazaki
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

Review 2.  Cx43 expression and function in the nervous system-implications for stem cell mediated regeneration.

Authors:  Carola Meier; Katja Rosenkranz
Journal:  Front Physiol       Date:  2014-03-18       Impact factor: 4.566

3.  Complete Restoration of Motor Function in Acute Cerebral Stroke Treated with Allogeneic Human Umbilical Cord Blood Monocytes: Preliminary Results of a phase I Clinical Trial.

Authors:  Tian-Kuo Lee; Cheng-You Lu; Sheng-Tzung Tsai; Pao-Hui Tseng; Yu-Chen Lin; Shinn-Zong Lin; Jonas C Wang; Chih-Yang Huang; Tsung-Lang Chiu
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

4.  Umbilical Cord Blood Mononuclear Cell Treatment for Neonatal Rats With Hypoxic Ischemia.

Authors:  Hao Lyu; Dong Ming Sun; Chi Ping Ng; Wendy S Cheng; Jun Fan Chen; Yu Zhong He; Sin Yu Lam; Zhi Yuan Zheng; Guo Dong Huang; Chi Chiu Wang; Wise Young; Wai Sang Poon
Journal:  Front Cell Neurosci       Date:  2022-03-02       Impact factor: 5.505

5.  A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy.

Authors:  Li Huang; Che Zhang; Jiaowei Gu; Wei Wu; Zhujun Shen; Xihui Zhou; Haixia Lu
Journal:  Cell Transplant       Date:  2018-02       Impact factor: 4.064

6.  Therapeutic mechanism of cord blood mononuclear cells via the IL-8-mediated angiogenic pathway in neonatal hypoxic-ischaemic brain injury.

Authors:  Kye Hee Cho; Jee In Choi; Jin-Ock Kim; Joo Eun Jung; Dong-Wook Kim; MinYoung Kim
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.